Consensus $44.98M. Narrows FY25 adjusted EBITDA loss view to $47M-$51M from $46M-$53M.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics options imply 14.6% move in share price post-earnings
- Aquestive appoints Davis as CDO, Slatko as interim CMO, Boyd as CPO
- Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm